Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04348045
Title Personalized Maintenance Therapy for m-PDAC Using Olaparib or Selumetinib + Durvalumab, Based on BRCAness and KRAS Status. (MAZEPPA)
Acronym MAZEPPA
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors GERCOR - Multidisciplinary Oncology Cooperative Group
Indications
Therapies
Age Groups: adult | senior
Covered Countries FRA


No variant requirements are available.